Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Placebo-controlled, Double-blind, Safety and Experience Evaluation of IgG Binding Protein LT (BP-LT).

This study evaluates the safety and tolerability of the food ingredient IgG Binding Protein LT (BP-LT) when added to a daily diet. BP-LT is a stable protein in…

Safety and Tolerability in Healthy Volunteers

Estimated

~$10 – $7,500

Bactolife A/SNCT07824011

Observational

A Randomized, Open-label, Evaluator-Blinded, Cross-over Clinical Study to Confirm the Safety and Tolerability of an Ultra Absorbency Menstrual Tampon Compared to a Commercially Marketed Tampon

A Randomized, Open-Label, Evaluator-Blinded, Cross-Over Clinical Study to Confirm the Safety and Tolerability of an Ultra Absorbency Menstrual Tampon Compared …

Safety and Tolerability in Healthy Volunteers

Estimated

~$10 – $8,750

Lyv Life Inc. (dba: Cora)NCT07807891

Phase 1

Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral MG001

This research study is the first time the new medication MG001 is being tested in people. MG001 is a formulation of mitragynine, a compound that comes from a p…

Safety and Tolerability in Healthy Subjects

Estimated

~$10 – $5,625

National Institute on Drug Abuse (NIDA)NCT07204171

Phase 1

Phase 1, Double-Blinded, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of AVR-48

This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profil…

Safety IssuesTolerabilityPharmacokinetics+1 more

Estimated

~$10 – $8,750

AyuVis Research, Inc.NCT06847698

Phase 1

A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors

This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and prelimina…

Safety IssuesTolerabilityPharmacokinetics

Estimated

~$10 – $8,750

Nanjing Immunophage Biotech Co., LtdNCT05142592